Samsung Biologics adds new manufacturing plant

By The Science Advisory Board staff writers

August 11, 2020 -- Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and manufacturing capabilities, in part due to COVID-19.

In total the company plans to invest over $2 billion in the two facilities, which will add 256-kiloliter capacity and begin manufacturing activities in the second half of 2022. The site will be the world's largest manufacturing facility at a single location. The plant will incorporate multiscale manufacturing by incorporating advantages from Samsung's three previous sites.

The 23.8 million sq m facility will incorporate real-time production schedule simulation with automation and the latest biomanufacturing technologies and utility supply-based optimization. The new site will contain streamlined application, smart disposal of high-concentration wastewater, and improvement of nitric acid emissions.

The company is also in negotiations with the authorities at the Incheon Free Economic Zone to purchase additional land for a second complex. This site is located near the company's current complex and will add 330,000 sq m of manufacturing space.

Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter